Enliven Therapeutics ELVN Total debt

Total debt at other companies

Bristol-Myers SquibbBMY

$43.33B-12.3%

PfizerPFE

$64.43B+4.9%

ImmunityBio, Inc.IBRX

$445.39M+32.2%

Iovance Biotherapeutics, Inc.IOVA

$46M-11.8%

Syndax PharmaceuticalsSNDX

$350.49M+4.2%

Cullinan Therapeutics, Inc.CGEM

$2.07M+36.3%

FAQ

What is Enliven Therapeutics's total debt?

Enliven Therapeutics (ELVN) reported total debt of $302K in Q1 2026.

How has Enliven Therapeutics's total debt changed year-over-year?

Enliven Therapeutics's total debt decreased by 56.9% year-over-year, from $700K to $302K.

What is the long-term trend for Enliven Therapeutics's total debt?

Over 2 years (2021 to 2025), Enliven Therapeutics's total debt has grown at a -21.8% compound annual growth rate (CAGR), from $652K to $399K.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.